Frazier Life Sciences Management, L.P.
In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 15, 2024), Frazier Life Sciences Management, L.P. reported 48 stock positions worth $2.1 billion. Its top holding was Newamsterdam Pharma (NAMS) at 11.0% of the portfolio, followed by Mirum Pharmaceuticals (MIRM, 10.4%) and Krystal Biotech (KRYS, 8.5%). Compared with Q1 2024, it opened 8 new positions, sold out of 9, added to 13 and reduced 4. The biggest buy was a new position in Erasca (ERAS) and the biggest sale an exit from Alpine Immune Sciences (ALPN).
- Most Recent 13F
- Q2 2026
- Location
- PALO ALTO, CA
- CIK
- 0001892134
- Portfolio Value
- $2.1B (Q2 2024)
- SEC Filing
- 0001892134-24-000004 ↗ filed Aug 15, 2024
Holdings Value
Holdings 48 stocks · $2.1B
| NAMS Newamsterdam Pharma Co. NV | 11.01% | 12,226,943 | $234.9M | No change |
| MIRM Mirum Pharmaceuticals Inc. | 10.41% | 6,495,392 | $222.1M | No change |
| KRYS Krystal Biotech Inc. | 8.51% | 988,460 | $181.5M | No change |
| HLVX Hillevax Inc. | 7.20% | 10,617,062 | $153.5M | Add +8.5% |
| PHAT Phathom Pharmaceuticals Inc. | 4.88% | 10,109,279 | $104.1M | No change |
| RYTM Rhythm Pharmaceuticals Inc. | 4.56% | 2,371,304 | $97.4M | Add +8.3% |
| BBIO Bridgebio Pharma Inc. | 4.31% | 3,632,604 | $92.0M | Add +6.3% |
| ARQT Arcutis Biotherapeutics Inc. | 3.83% | 8,785,284 | $81.7M | No change |
| IRON Disc Medicine Inc. | 3.71% | 1,754,834 | $79.1M | Add +123.5% |
| PCVX Vaxcyte Inc. | 3.68% | 1,039,405 | $78.5M | Reduce -8.8% |
| EWTX Edgewise Therapeutics Inc. | 3.15% | 3,731,067 | $67.2M | Add +12.9% |
| ANAB Anaptysbio Inc. | 2.54% | 2,165,591 | $54.3M | Add +140.7% |
| VRNA Verona Pharma Ltd. | 2.25% | 3,314,349 | $47.9M | Add +9.9% |
| KALV Kalvista Pharmaceuticals Inc. | 2.04% | 3,687,867 | $43.4M | No change |
| TARS Tarsus Pharmaceuticals Inc. | 2.02% | 1,587,527 | $43.1M | Reduce -11.2% |
| RVMD Revolution Medicines Inc. | 1.81% | 997,455 | $38.7M | No change |
| ERAS Erasca Inc. | 1.79% | 16,216,216 | $38.3M | New |
| AGIO Agios Pharmaceuticals Inc. | 1.76% | 871,974 | $37.6M | Add +66.7% |
| SLNO Soleno Therapeutics Inc. | 1.67% | 875,667 | $35.7M | No change |
| RCKT Rocket Pharmaceuticals Inc. | 1.58% | 1,561,230 | $33.6M | No change |
| SVRA Savara Inc. | 1.54% | 8,157,385 | $32.9M | Add +103.9% |
| ORIC Oric Pharmaceuticals Inc. | 1.37% | 4,142,855 | $29.3M | No change |
| CGON CG Oncology Inc. | 1.14% | 770,000 | $24.3M | No change |
| PEPG Pepgen Inc. | 1.12% | 1,502,788 | $24.0M | No change |
| MRUS Merus NV | 1.03% | 373,100 | $22.1M | Reduce -50.0% |
| TRVI Trevi Therapeutics Inc. | 1.03% | 7,381,090 | $22.0M | No change |
| SLN Silence Therapeutics PLC-ADR | 1.02% | 1,148,591 | $21.8M | No change |
| RARE Ultragenyx Pharmaceutical Inc. | 0.82% | 425,000 | $17.5M | New |
| AUTL Autolus Therapeutics PLC | 0.75% | 4,623,324 | $16.1M | No change |
| CERE Cerevel Therapeutics Holding | 0.75% | 393,000 | $16.1M | No change |
| MREO Mereo Biopharma Group PL-ADR | 0.74% | 4,401,371 | $15.8M | New |
| IMTX Immatics NV | 0.63% | 1,152,456 | $13.4M | New |
| TYRA Tyra Biosciences Inc. | 0.62% | 832,220 | $13.3M | No change |
| MGNX Macrogenics Inc. | 0.60% | 3,010,727 | $12.8M | Add +21.8% |
| APLT Applied Therapeutics Inc. | 0.50% | 2,286,135 | $10.7M | Add +17.1% |
| PBYI Puma Biotechnology Inc. | 0.47% | 3,062,558 | $10.0M | Add +8.7% |
| ETNB 89BIO Inc. | 0.38% | 1,000,000 | $8.0M | No change |
| ELEV Elevation Oncology Inc. | 0.37% | 2,958,579 | $8.0M | New |
| COGT Cogent Biosciences Inc. | 0.37% | 936,576 | $7.9M | No change |
| ACAD Acadia Pharmaceuticals Inc. | 0.36% | 470,338 | $7.6M | No change |
| ARVN Arvinas Inc. | 0.36% | 285,331 | $7.6M | No change |
| ADVM Adverum Biotechnologies Inc. | 0.34% | 1,069,244 | $7.3M | New |
| ALLO Allogene Therapeutics Inc. | 0.31% | 2,867,750 | $6.7M | No change |
| ANTX AN2 Therapeutics Inc. | 0.21% | 2,088,889 | $4.5M | Add +50.4% |
| DSGN Design Therapeutics Inc. | 0.19% | 1,195,179 | $4.0M | New |
| IMCR Immunocore Holdings PLC-ADR | 0.17% | 108,762 | $3.7M | New |
| MGX Metagenomi Therapeutics Inc. | 0.05% | 245,692 | $1.0M | Reduce -11.9% |
| ACRS Aclaris Therapeutics Inc. | 0.01% | 264,377 | $291K | No change |
Other holdings (1): bonds, preferreds, convertibles and warrants · $4.4M (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| NAMSW Newamsterdam Pharma Co. NV-27 | *W EXP 99/99/999 | 500,333 | $4.4M | No change |
Total filed on the 13F, all lines: $2.1B.
Portfolio Sells Q1 2024 → Q2 2024
| ALPN Alpine Immune Sciences Inc. | Sold out | 0.00% | −5.25 |
| APLS Apellis Pharmaceuticals Inc. | Sold out | 0.00% | −2.20 |
| AEROVATE THERAPEUTICS INC | Sold out | 0.00% | −1.51 |
| GPCR Structure Therapeutics Inc. | Sold out | 0.00% | −1.14 |
| DCPH Deciphera Pharmaceuticals Inc. | Sold out | 0.00% | −0.97 |
| TARS Tarsus Pharmaceuticals Inc. | Reduce -11.2% | 2.02% | −0.73 |
| ADVM Adverum Biotechnologies Inc. | Sold out | 0.00% | −0.64 |
| MRUS Merus NV | Reduce -50.0% | 1.03% | −0.39 |
| NTLA Intellia Therapeutics Inc. | Sold out | 0.00% | −0.24 |
| GRITSTONE BIO INC | Sold out | 0.00% | −0.11 |
| BLUEBIRD BIO INC | Sold out | 0.00% | −0.09 |
| MGX Metagenomi Therapeutics Inc. | Reduce -11.9% | 0.05% | −0.08 |
| PCVX Vaxcyte Inc. | Reduce -8.8% | 3.68% | +0.39 |
Portfolio Buys Q1 2024 → Q2 2024
| ERAS Erasca Inc. | New | 1.79% | +1.79 |
| ANAB Anaptysbio Inc. | Add +140.7% | 2.54% | +1.69 |
| IRON Disc Medicine Inc. | Add +123.5% | 3.71% | +1.64 |
| AGIO Agios Pharmaceuticals Inc. | Add +66.7% | 1.76% | +1.12 |
| RARE Ultragenyx Pharmaceutical Inc. | New | 0.82% | +0.82 |
| MREO Mereo Biopharma Group PL-ADR | New | 0.74% | +0.74 |
| SVRA Savara Inc. | Add +103.9% | 1.54% | +0.70 |
| IMTX Immatics NV | New | 0.63% | +0.63 |
| EWTX Edgewise Therapeutics Inc. | Add +12.9% | 3.15% | +0.60 |
| RYTM Rhythm Pharmaceuticals Inc. | Add +8.3% | 4.56% | +0.55 |
| ELEV Elevation Oncology Inc. | New | 0.37% | +0.37 |
| ADVM Adverum Biotechnologies Inc. | New | 0.34% | +0.34 |
| HLVX Hillevax Inc. | Add +8.5% | 7.20% | +0.32 |
| VRNA Verona Pharma Ltd. | Add +9.9% | 2.25% | +0.20 |
| DSGN Design Therapeutics Inc. | New | 0.19% | +0.19 |
| IMCR Immunocore Holdings PLC-ADR | New | 0.17% | +0.17 |
| ANTX AN2 Therapeutics Inc. | Add +50.4% | 0.21% | +0.02 |
| APLT Applied Therapeutics Inc. | Add +17.1% | 0.50% | −0.06 |
| BBIO Bridgebio Pharma Inc. | Add +6.3% | 4.31% | −0.15 |
| PBYI Puma Biotechnology Inc. | Add +8.7% | 0.47% | −0.16 |
| MGNX Macrogenics Inc. | Add +21.8% | 0.60% | −0.94 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 40 | $4.6B | MIRM, NAMS, ERAS, MBX, ARQT |
| Q1 2026 | 37 | $3.9B | MIRM, NAMS, ERAS, BBIO, ARQT |
| Q4 2025 | 39 | $3.7B | NAMS, MIRM, ARQT, BBIO, MBX |
| Q3 2025 | 46 | $3.3B | MIRM, NAMS, VRNA, BBIO, ARQT |
| Q2 2025 | 48 | $2.5B | MIRM, VRNA, NAMS, BBIO, ARQT |
| Q1 2025 | 46 | $2.2B | NAMS, MIRM, VRNA, ARQT, BBIO |
| Q4 2024 | 49 | $2.4B | NAMS, MIRM, VRNA, KRYS, ARQT |
| Q3 2024 | 52 | $2.5B | MIRM, NAMS, PHAT, KRYS, MBX |
| Q2 2024 | 48 | $2.1B | NAMS, MIRM, KRYS, HLVX, PHAT |
| Q1 2024 | 49 | $2.4B | NAMS, KRYS, MIRM, HLVX, ALPN |